



---

# Turner syndrome—issues to consider for transition to adulthood

Laura Lucaccioni<sup>†</sup>, Sze Choong Wong<sup>†</sup>, Arlene Smyth<sup>‡</sup>, Helen Lyall<sup>§</sup>, Anna Dominiczak<sup>\*\*</sup>, S. Faisal Ahmed<sup>†</sup>, and Avril Mason<sup>†,\*</sup>

<sup>†</sup>Developmental Endocrinology Research Group, School of Medicine, University of Glasgow, Dalnair Street, Glasgow, UK, <sup>‡</sup>Turner Syndrome Support Society, 12 Simpson Court, Clydebank, UK, <sup>§</sup>Assisted Conception Unit, Glasgow Royal Infirmary, Castle Street, Glasgow, UK, and <sup>\*\*</sup>College of Medicine, Veterinary and Life Sciences, University of Glasgow, University Avenue, Glasgow, UK

\*Correspondence address. Endocrine Services, Royal Hospital for Sick Children, Yorkhill, Glasgow G3 8SJ, UK. E-mail: [avrilmason@nhs.net](mailto:avrilmason@nhs.net); [Avril.mason@ggc.scot.nhs.uk](mailto:Avril.mason@ggc.scot.nhs.uk)

Accepted 6 November 2014

## Abstract

**Background:** Turner syndrome (TS) is associated with a spectrum of health problems across the age span, which requires particular attention during the transition period in these adolescents.

**Areas of agreement:** The majority of girls with TS require oestrogen replacement from puberty onwards, which is important for adequate feminization, uterine development and maintenance of bone health. There is a lifetime increased risk from autoimmune conditions like hypothyroidism, coeliac disease, hearing loss and aortic dilatation with the potential to lead to aortic dissection. A systematic and holistic approach to provision of health care in TS is needed.

**Areas of controversy:** Several unanswered questions remain, including the choice of hormone replacement therapy in the young person with TS and in adulthood; the optimal mode of cardiovascular assessment; the best management and assessment prior to and during pregnancy.

**Areas timely for developing research:** The optimal model of care and transition to adult services in TS requires attention. Further research is needed in relation to cardiovascular risk assessment, pregnancy management and hormone replacement therapy in TS.

**Key words:** Turner syndrome, transition, hormone replacement therapy, puberty, pregnancy, aortic dissection, aortic dilatation

---

## Background

Turner syndrome (TS) is a condition in phenotypic girls and women with a lack of one or part of one sex chromosome and affects ~1/2500 live female births.<sup>1</sup> While short stature, hypogonadism and typical dysmorphic features are commonly recognized clinical features, a range of medical problems can exist across the age span (Table 1). Paediatric management has often focussed on the use of recombinant human growth hormone (rhGH) to improve linear growth and the timely use of sex steroid to mimic normal pubertal development. Medical issues like aortic dilatation (AD) and dissection, bone health, hearing loss, liver dysfunction, autoimmune conditions and cancer risks may have a major impact on the life of these girls and women. With the advent of modern techniques of assisted reproduction technologies, many TS women are seeking the opportunity for childbearing. However, associated medical problems such as AD and autoimmune conditions (e.g. undiagnosed hypothyroidism) may contribute to significant risks in these pregnancies.<sup>2,3</sup> It is, therefore, imperative that a comprehensive health assessment in girls with TS is performed at the time of transition and continues to be addressed in adulthood by clinicians cognizant with the unique and inter-related issues encountered by these women. Careful counselling of these young individuals and their families at this critical period is also imperative.

It is accepted that the diagnosis of TS is reached with standard banded karyotype, counting 15–30 cells. If low-level mosaicism is suspected, increasing the number of cell count to 100 cells may be necessary, which allows for detection of 3% mosaicism at 95% confidence levels.<sup>4</sup> Only ~50% of TS individuals have a 45, X karyotype and 40% will have a structural abnormality of the second X chromosome. Approximately 30% of TS will have a mosaic peripheral blood karyotype, where a 45, X cell line coexists with one non-45, X cell line.<sup>5,6</sup> Importantly, 10% of women with TS have mosaicisms for a cell line with a normal or abnormal Y chromosome. The risk of gonadoblastoma in these individuals is estimated to be ~30% and early gonadectomy is recommended.<sup>7</sup> The majority of TS with mosaic karyotype will not have the classical features of TS, and a low threshold

for investigations is encouraged to avoid late diagnosis. In many genetic laboratories, DNA microarrays are increasingly used to make the diagnosis of TS. The accuracy of detection of low-level mosaicism and Y chromosome material is still unclear.<sup>8</sup>

Current expert consensus recommends performing karyotype in girls with any of the following: short stature, delayed puberty, webbed neck, lymphoedema, inner ear problems and coarctation of aorta (CoA).<sup>9</sup> The prevalence of TS in girls presenting with short stature is between 2 and 4%, and its prevalence in girls presenting with CoA is at least 5%.<sup>10,11</sup> Delayed diagnosis of TS in adolescence and beyond is still seen in ~20% of diagnosed cases. This clinical review aims to summarize the important health issues that need to be considered by a clinician preparing a young person with TS for transition to adult care.

## Pubertal development in TS

TS is associated with hypergonadotropic hypogonadism, as a consequence of premature ovarian failure. Approximately 30% of girls with TS enter puberty spontaneously, but only ~4% reach menarche and only 1% are fertile. Almost 90% will require hormone replacement therapy either to initiate and/or to ensure progress in puberty, maintain secondary sexual development and promote bone health.<sup>12</sup> The pattern of gonadotrophins (Gn) secretion in TS is similar to that observed in normal pre-pubertal girls, but serum concentrations are consistently higher at all pre-pubertal ages. Assessment of ovarian function in childhood using Gn may be unhelpful due to the relative quiescence of the hypothalamic pituitary gonadal axis. Concentration of antimüllerian hormone (AMH), produced by granulosa cell, has been found to remain stable from mid-childhood to early adulthood and can be used to evaluate ovarian function throughout the age range. AMH may help predict those girls who will achieve spontaneous onset of puberty and normal pubertal progress as well as the presence of healthy follicles.<sup>13,14</sup>

## Sex steroid replacement in TS

The optimal regimen for sex steroid replacement for induction of puberty in TS remains a controversial

**Table 1** Clinical features in Turner syndrome

	Neonate and childhood	Adolescence and adult age
Specific physical features	<p>Neonate:</p> <ul style="list-style-type: none"> <li>- Redundant nuchal skin</li> <li>- Puffiness of the hands and feet</li> </ul> <p>Childhood:</p> <ul style="list-style-type: none"> <li>- Short stature</li> <li>- Short neck</li> <li>- Characteristic facies with micrognathia</li> <li>- Abnormal upper-to-lower segment ratio</li> <li>- Orthopaedic stigma:               <ul style="list-style-type: none"> <li>- Short metacarpals</li> <li>- Madelung deformity</li> <li>- Scoliosis</li> <li>- Genu valgum</li> <li>- Cubitus valgus</li> </ul> </li> </ul>	Short stature
Lymphatic system	<p>Foetus failed to survive: obstructed jugular lymphatics with nuchal cystic hygromas due to cardiovascular failure</p> <p>Neonate: peripheral lymphedema and webbed neck (residual of the cystic hygroma)</p>	Lymphedema may occur at any age and be exacerbated by treatments as growth hormone or oestrogens
Bone	<p>Congenital hip dislocation</p> <p>Scoliosis and kyphosis</p>	<p>Scoliosis and kyphosis</p> <p>Osteopenia and osteoporosis due to lack of oestrogen production</p>
ENT	<p>Otitis media due to an abnormal relationship between the eustachian tube and middle ear</p> <p>Progressive sensorineural hearing loss</p>	Progressive sensorineural hearing loss
Renal	<p>Congenital urinary system malformations:</p> <ul style="list-style-type: none"> <li>- Horseshoe kidneys</li> <li>- Malrotations</li> <li>- Other positional abnormalities</li> </ul> <p>Urinary tract infections</p>	Risk to develop hypertension and frequent urinary tract infections

Table continues

**Table 1** Continued

	Neonate and childhood	Adolescence and adult age
Eyes	<p>Abnormalities of the external ocular adnexa:</p> <ul style="list-style-type: none"> <li>- Epicanthal folds</li> <li>- Ptosis</li> <li>- Hypertelorism</li> <li>- Upward slanting palpebral fissures</li> </ul> <p>Strabismus and hyperopia, high risk of amblyopia</p>	
Cardiovascular system	<p>Congenital heart disease:</p> <ul style="list-style-type: none"> <li>- Bicuspid aortic valves</li> <li>- Coarctation of aorta</li> <li>- Aortic dilatation</li> <li>- Partial anomalous pulmonary connection</li> <li>- Persistent left superior vena cava</li> </ul>	<p>High risk of aortic dissection or rupture due to aortic dilation</p> <p>Generalized dilation of major vessels including the brachial and carotid arteries as well as the aorta</p> <p>Electrocardiographic conduction and repolarization abnormalities: right axis deviation, T-wave abnormalities, accelerated AV conduction and QTc prolongation</p> <p>Systemic hypertension</p>
Growth	<p>Mild intra-uterine growth retardation</p> <p>Slow growth during infancy</p> <p>Delayed onset of the childhood component of growth</p> <p>Growth failure during childhood</p>	<p>Absence of a pubertal growth spurt</p> <p>Short stature</p>
Mental development	<p>Normal intelligence with selective impairment in non-verbal perceptual motor and visuospatial skills</p> <p>Attention deficit disorder</p>	<p>Increased risk of social isolation, immaturity and anxiety</p> <p>Higher levels of shyness and social anxiety and reduced self-esteem</p>
Puberty and pregnancy	<p>Lack of spontaneous pubertal development onset</p>	<p>Hypergonadotrophic hypogonadism due to primary ovarian failure</p> <p>Absent or partial pubertal development</p> <p>Infertility</p> <p>Increased rate of maternal complications in TS who achieved pregnancy (dilatation and dissection of the aorta, diabetes, hypothyroidism)</p>
Gastrointestinal system and liver	<p>Coeliac disease</p>	<p>Inflammatory bowel diseases</p> <p>Liver enzymes raised</p> <p>High risk of steatosis, steatofibrosis and steatohepatitis</p> <p>Marked architectural changes due to portal hypertension</p>
Autoimmunity and endocrine	<p>Autoimmune thyroiditis</p> <p>Coeliac disease</p> <p>Diabetes mellitus</p>	<p>Alopecia</p> <p>Vitiligo</p> <p>Obesity and diabetes mellitus</p>

**Table 2** Development and maintenance of puberty in TS—local approach

Age (years)	Aim of therapy	Year 1		Year 2		Year 3	
12+	Pubertal induction (suggested doses):						
		Oral ethinyloestradiol ( $\mu\text{g}$ )	2		4	6/8/10 <sup>a</sup>	
		Patch 17 $\beta$ -oestradiol ( $\mu\text{g}$ )	6.25	12.5	25	50 <sup>a</sup>	50
15+	Completion of puberty (suggested doses):			Year 4 onwards			
		Oral ethinyloestradiol ( $\mu\text{g}$ )			20–30 <sup>a</sup>		
		Patch 17 $\beta$ -oestradiol ( $\mu\text{g}$ )			50–100 <sup>a</sup>		

<sup>a</sup>Norethisterone 5 mg daily for the first 5 days of each calendar month when ethinyloestradiol reaches 10  $\mu\text{g}$  daily, or when breakthrough bleeding occurs, whichever is the sooner.

issue. The timing of introduction of oestrogen, the type, dose and route of oestrogen administration may impact on health outcomes. The main goals of sex steroid replacement in puberty are to ensure (i) adequate breast development, (ii) pubertal growth spurt, (iii) adequate uterine development and (iv) bone accrual for adequate peak bone mass. Our current clinical practice for pubertal induction is summarized in Table 2. For a more comprehensive review on aspects on the area of sex steroid replacement in TS, the reader is referred to two recent excellent reviews of the topic.<sup>15,16</sup>

Generally, oestrogen is initiated around the age of 12–13 years if there are no signs of breast development or progression in pubertal status. The combined effect of rhGH and low doses of oestrogens seems to influence height velocity in a favourable way, while supra-physiological oestrogen doses given too early might limit the GH-dependent gain in final height.<sup>17,18</sup> Oestrogen is gradually increased over a 2–3 year period to mimic the physiological rise in levels to ensure adequate breast development and pubertal growth spurt. Delaying sex steroid treatment until the completion of linear growth, a practice common previously, undervalues the psychosocial importance of age-appropriate pubertal maturation and may be deleterious to bone development and other aspects of the child's health.<sup>19</sup> Healthy pre-pubertal girls, in fact, secrete low but measurable amount of oestradiol.<sup>20,21</sup> Given the effects of oestrogen on various target organs, it is thought that delaying sex steroid

replacement to >12 years may lead to unfavourable clinical outcome. A recent randomized placebo trial of ultra-low-dose oral ethinyl oestradiol introduced as young as 5 years show that it may lead to more physiological onset of pubertal development, more favourable augmentation of rhGH growth and benefits for cognition.<sup>22,23</sup> This is not conventional practise and further research is needed.

Optimizing uterine growth is fundamental in improving success rates of pregnancy in the future. The window of opportunity (during puberty and post-pubertal/pre-conception) and outcome in TS is unclear. In the UK, oral ethinyl oestradiol commencing at 2  $\mu\text{g}$  daily at age 12–13 years is commonly used. This leads to satisfactory pubertal induction and maintenance, but may fail to induce a fully mature uterus in about half of the affected population without spontaneous pubertal onset.<sup>12</sup> The ethinyl component of ethinyl oestradiol also induces prorenin substrate product at a much higher rate than natural oestrogen and may lead to an increase in blood pressure in a cohort of patient where hypertension is relatively common.<sup>24</sup>

There are also possible advantages of transdermal oestrogen over oral oestrogen including a more physiologic delivery, decreased first pass metabolism and higher systemic IGF1 levels with possible consequent improvement in metabolism and body composition.<sup>25–27</sup> While studies in adult hypopituitary and postmenopausal women treated with oral 17 $\beta$ -oestradiol showed reduction in IGF1 levels, with

consequent reduction in lipid oxidation, whole-body protein synthesis, lean mass and increase in fat mass,<sup>28,29</sup> less is known about the effects of oral oestrogen in childhood and puberty. In girls with short stature, oral 17 $\beta$ -oestradiol leads to reduction in IGF1 levels following short-term rhGH injections as part of the IGF generation test.<sup>30</sup> However, a pilot, randomized controlled trial of oral conjugated oestrogen vs. transdermal 17 $\beta$ -oestradiol for pubertal induction in 12 girls with TS showed no differences in systemic IGF1 levels. Transdermal 17 $\beta$ -oestradiol however led to better bone accrual and increased uterine growth compared with oral conjugated oestrogen.<sup>31</sup>

Table 3 summarizes the currently published studies of pubertal induction with oestrogen on uterine development in TS. The summary highlights the heterogeneity of the current published studies (number of cases, study design, oestrogen regime). It is, however, noteworthy that most were commenced on oestrogen relatively late. One recent randomized controlled trial show that transdermal 17 $\beta$ -oestradiol used to induce puberty in TS was superior to oral conjugated oestrogen with regards to uterine development.<sup>31</sup> A study in 25 adult women (including 7 with TS) with primary hypogonadism showed that women managed with transdermal oestrogen containing 17 $\beta$ -oestradiol (Estraderm patches) showed a trend towards increase in uterine volumes compared with an oral contraceptive pill containing ethinyl oestradiol (Loestrin 30).<sup>39</sup> These early studies point to the possible benefit of transdermal oestrogen for pubertal induction and replacement therapy, and there may still be an opportunity to optimize uterine volume post puberty, although the magnitude of this is currently unknown.

At the end of this period of increasing doses of oestrogen, progesterone is added at least every 3 months to allow endometrial shedding, although some girls may prefer a monthly bleed. In the UK, common forms of oestrogen replacement post induction of puberty are the oral contraceptive pill, oral oestrogen/oral progesterone, combined transdermal patch and transdermal patch/oral oestrogen.<sup>40</sup> Decisions of ongoing oestrogen replacement need to be carefully discussed with the young person and family during transition and management may need to be individualized.

From a cardiovascular point of view, oral oestrogen replacement may be associated with a higher risk of hypertension, stroke, venous thromboembolism (VTE) and coronary heart disease in predisposed women.<sup>41</sup> In comparison with a 12-month oral regimen (ethinylestradiol 30.0  $\mu$ g and norethisterone 1.5 mg daily for Weeks 1–3, followed by 7 ‘pill-free’ days), physiological replacement with transdermal oestrogen (transdermal oestradiol 100  $\mu$ g daily for Week 1 and 150  $\mu$ g for Weeks 2–4 plus oral or vaginal progestins of progesterone 200 mg twice daily in Weeks 3–4) resulted in lower blood pressure, better renal function (plasma angiotensin II and serum creatinine concentrations) and less activation of the renin-angiotensin system in women with premature ovarian failure.<sup>42</sup> These differences potentially have major consequences for the future long-term cardiovascular risk in TS. Oral oestrogens are unable to reach the systemic circulation directly and are usually first metabolized by intestine and liver. Thus, the liver is exposed to a higher dose of oestrogen than the rest of the body, stimulating the production of hepatic proteins as renin substrate, which may exacerbate hypertension and triggering changes between antithrombotic mechanisms and pro-coagulant factors.<sup>12</sup> Although VTE can occur at any time, the risk is highest in the first year of treatment. Both the risk for VTE and education regarding thrombosis prevention should be discussed with the young person and her family. Transdermal oestradiol and micronized progesterone are preferable for girls with TS who have an increased risk of VTE, but these need to be balanced against the possibility of poor adherence with transdermal treatment.

## Bone health

As discussed earlier, appropriate timing of introduction of oestrogen for induction of puberty in TS is needed for achievement of peak bone mass. Oestrogen stimulates endocortical formation with resultant narrowing of the medullary cavity. Bone health is thought to be variably affected in TS, although older studies using dual energy absorptiometry (DXA) evaluation have not adjusted for the relative short stature of these individuals. Thus, TS individuals are

**Table 3** Effects of pubertal induction regimen on uterine outcomes and on bone development

Reference	Study design	Number of subjects	Mean/Median age starting oestrogen	Form of oestrogen and dose	Outcome
Effect of pubertal induction regimen on uterine outcome					
Nabhan <i>et al.</i> <sup>31</sup>	Randomized controlled trial	12 (6 in each group)	14 years	Oral CE: 0.3 increasing to 0.625 mg/day Transdermal E (TE): 0.025 increasing to 0.0375 mg/day	↑ uterine length in TE (66% mature uterus in TE, 0% mature uterus in oral CE)
Kim <i>et al.</i> <sup>32</sup>	Retrospective	9 10	14.5 years 15.9 years	Oral EV: 0.5–2 mg increasing Oral EV: 1–2 mg increasing	Oral EV 1 mg ↑ uterine size (50% mature uterus in 1 mg group, 22% mature uterus in 0.5 mg group)
Cleemann <i>et al.</i> <sup>33</sup>	Cross-sectional	41	13 years	Oral E: 0.1–1.75 mg increasing	↓ uterine volume
Bannink <i>et al.</i> <sup>34</sup>	Prospective non-randomized	56	12.7 years	Oral E: 5 µg/kg/day increasing to 10 µg/kg/day	↓ uterine volume Mature adult shaped fundus-cervical ratio uterus in 79.5%
Piippo <i>et al.</i> <sup>35</sup>	Prospective, non-randomized	23	13.6 years	Gel E: 0.1 mg/day increasing to 1.5 mg/day	Normal uterine size
Doerr <i>et al.</i> <sup>36</sup>	Prospective, non-randomized	75	14.7 years	Oral EE Oral CE Oral EV OCP	↓ uterine volume, but no group details. Only 45 X0/46 XX individuals with normal uterine length and volume
McDonnell <i>et al.</i> <sup>37</sup>	Prospective, non-randomized	13	14.6 years	Oral CE 0.25 mg increasing to 2 mg	Normal uterine volume
Snajderova <i>et al.</i> <sup>38</sup>	Cross-sectional	57	14.6 years	Oral E 5 µg/kg/day increasing to 15–20 µg/kg/day	63% hypoplastic uterus
Paterson <i>et al.</i> <sup>12</sup>	Retrospective	14 (Tanner 5)	10–21.6 years	EE 1 µg/day increasing to 30 µg/day	Normal uterine length but only 50% mature adult configuration
Effect of pubertal induction regimen on bone development					
Nabhan <i>et al.</i> <sup>31</sup>	Randomized controlled trial	12 (6 in each group)	14 years	Oral CE: 0.3 increasing to 0.625 mg/day Transdermal E (TE): 0.025 increasing to 0.0375 mg/day	↑ absolute spine BMC, BMD and BMD Z-score in TE
Kim <i>et al.</i> <sup>32</sup>	Retrospective	9 10	14.5 years 15.9 years	Oral EV: 0.5–2 mg increasing Oral EV: 1–2 mg increasing	No differences in BMD between groups

CE, conjugated oestrogen; E, 17β-oestradiol; EV, oestradiol valerate; EE, ethinyloestradiol; OCP, oral contraceptive pill.

often reported to have low bone mass when age matched but not height matched. In addition, some older reports may have included individuals who had very late introduction of oestrogen for pubertal induction. Table 3 summarizes the currently published studies of pubertal induction with oestrogen on bone development.

For adequate maintenance of bone health in adulthood, the conventional use of the oral contraceptive pill (OCP) may be contraindicated and may lead to ongoing bone loss as the woman with TS will be oestrogen deficient for 7 days out of the 30-day cycle. In some countries, there is now an OCP which allows for only two oestrogen-free days. The degree of possible bone loss in TS on either of these regimes is unknown. Identifying and managing other associated clinical conditions that may predispose to further insults to bone health in TS including coeliac disease (CD), inflammatory bowel disease (IBD) and thyroid dysfunction is also important.

A recent study revealed that TS adolescents (mean 13 years) may have lower size adjusted bone mineral apparent density (BMAD) at femoral neck but not at lumbar spine and lower cortical volumetric bone density on peripheral quantitative computer tomography. Most TS individuals under 13 years of age are unlikely to have completed puberty, whereas the majority of the reference group of girls would have achieved menarche at that age with a significant increase in bone mass accrual.<sup>43</sup> A more recent study in adults (mean age 30 years) showed that trabecular microarchitecture however may be abnormal in TS.<sup>44</sup> Currently, it is unclear whether the bone abnormalities in TS are related to adequacy of oestrogen replacement or whether it is also a non-progressive phenotype of the skeletal dysplasia associated with the syndrome. Longitudinal studies of bone mass in adults with TS especially in relation to HRT regimes are now needed.

### Pregnancy and fertility

Spontaneous pregnancies are very rare (2%) in women with TS. The likelihood of functional ovarian tissue and fertility in women with TS relies on the presence of 46,XX germ cells in the ovaries and is therefore more likely in women with mosaicism.

Advances in reproductive medicine, involving *In Vitro* Fertilization—Embryo Transfer (IVF-ET), have increased the possibility of childbearing in infertile women with TS, but pregnancy remains particularly challenging due to the high prevalence of serious, life-threatening cardiovascular complications such as aortic dissection (AoD).

Despite recent advances, there is an excess of foetal malformations, spontaneous abortion, intra-uterine growth restriction, low birth weight, prematurity and perinatal death in the offspring of mothers with TS irrespective of the method of conception, due to chromosomal and uterine abnormalities. However, a recent report of 106 TS women has provided more favourable neonatal outcome data, with a preterm birth rate of 8% and a low birth weight rate of ~9% in singletons.<sup>45</sup> Major birth defects were found in 4% of the children, not different from pregnancies after conventional IVF and better than previously reported. The perinatal mortality was 2%, including a set of extremely preterm twins. Maternal risks were high in this group, particularly in the development of hypertensive disorders. Heterologous IVF-ET, using oocyte donation, is the most used reproductive technique and it represents the only way to become pregnant for the vast majority of such women in whom ovarian failure is likely to be established at the time of starting a family. A review of 23 women with TS following ovum donation reported a miscarriage rate of 44% and take home baby rate of 18% per transfer.<sup>46</sup> In a further cohort of 30 women following oocyte donation, 26% of clinical pregnancies ended in miscarriage, much lower than the miscarriage rate of 45% using the patient's own gametes.<sup>47</sup>

Women with mosaic TS may also benefit from cryopreservation of patient's own oocytes for fertility preservation before decline in ovarian function. A report regarding 57 TS girls has informed the selection criteria among girls with TS who would be candidates and should be offered sampling and storing of ovarian tissue for cryopreservation.<sup>48</sup> This report concluded that at the age of 13–14 years, girls with TS should be counselled about fertility options and, in those with mosaic karyotype and spontaneous puberty in the absence of any elevation in follicle stimulating hormone (FSH) or reduction in AMH, the



discussion should include cryopreservation. Harvesting of oocytes or ovarian tissue from girls with TS for storage is technically possible, but these techniques remain experimental and have as yet not been associated with reported pregnancies published in the literature as far as we are aware.

## Cardiovascular health

Congenital heart disease (CHD) is a common association of TS and reported in up to 50%.<sup>49</sup> Bicuspid aortic valves (BAV), CoA and AD significantly contribute to the risk of AoD, although in 10% of reported cases no risk factors were reported. Hypertension is also relatively common and may require careful evaluation with 24 h blood pressure monitoring. AoD in TS, 6 times commoner than in healthy individuals, occurs frequently in the third decade as opposed to the seventh decade, although paediatric cases are seen. Symptoms are often non-specific including chest pain, non-specific gastrointestinal symptoms and musculoskeletal complaints but also change in phonation due to compression on recurrent laryngeal nerves, highlighting the importance of early recognition by TS individuals and medical staff. A recent comprehensive review on AD and dissection in TS includes a thorough review of the 122 published cases of AoD in these individuals.<sup>50</sup> As discussed in the previous section, pregnancy is a critical period. The risk of mortality from AoD alone during pregnancy in TS is in excess of 100 times the population risk.<sup>51</sup> The highest risk period during pregnancy is the third trimester although several cases reported have dissected within the first 2 weeks postpartum BAV, the commonest cardiovascular system (CVS) pathology, is seen in ~20% of individuals, although magnetic resonance imaging (MRI) reveal a spectrum of other abnormal aortic valves. CoA presenting with neonatal collapse, often but not universally associated with low birth weight and pedal oedema seen in ~4–12% of infants, may be the most well-recognized cardiac pathology. CoA may also present later in life with uncontrolled hypertension, or limb claudication diagnosed only on MRI.<sup>52</sup>

Ongoing CVS monitoring of all individuals with TS throughout adult life and during pregnancy is

recommended. Careful re-evaluation using MRI or detailed echocardiogram should be performed in adolescence before transfer to adult care to allow for appropriate counselling of risk. MRI should be used in adults and older adolescents with broad chests as adequate views are often not obtained with echocardiogram. Evaluation with MRI for evaluation of aortic arch dimensions may be better with MRI. Given that most girls with TS are relatively short even with rhGH therapy, aortic dimensions need to adjust for body surface area called aortic sized index (ASI). There is now sufficient evidence that TS with ASI of >2.0 and >2.5 cm/m<sup>2</sup> is at high risk and very high risk of AoD, respectively.<sup>53</sup> New data propose a mathematical model incorporating aortic dimensions and other clinical factors to identify TS individuals at greatest risk for AoD, although this is not validated against the clinical outcome of AoD.<sup>54</sup>

Despite the recognized importance of CVS monitoring, the majority of TS individuals do not currently have CVS monitoring. One study reported that only 40% of those undergoing oocyte donation had any form of CVS evaluation.<sup>55</sup> A single-centre approach with involvement of one endocrinologist and cardiologist on the other hand showed that ~70% of TS women had evaluation with echocardiogram and MRI.<sup>56</sup> Despite the recognition of ongoing monitoring, several controversies exist in particular to CVS issues especially during pregnancy. Two international expert consensus differ in recommendations of CVS risk contraindicating pregnancy in TS (Table 4),<sup>57,58</sup> and it is in this respect that further research and local consistencies in advice is needed.

We believe that TS individuals should be reviewed by cardiologists with experience in assessment of these girls and women, ideally by the Congenital Heart Disease Team. In a recent study, 40% of women with TS had abnormal cardiovascular findings which may preclude pregnancy when assessed by cardiologist with expertise in TS after having had normal assessments by previous cardiologists not familiar with TS.<sup>55</sup>

## Other health and psychosocial issues

Autoimmune and inflammatory conditions are commoner in TS. Hypothyroidism occurs in up to 30%,

**Table 4** International expert consensus in recommendations of CVS risk contraindicating pregnancy in TS

Consensus	Recommendations	Criteria
American Society for Reproductive Medicine (2012)	Absolute contraindication	Any significant cardiac abnormality and/or ASI >2 cm/m <sup>2</sup>
French College of Obstetricians and Gynaecologists (2010)	Contraindication	History of aortic surgery Previous aortic dissection Aortic dilatation (ASI >2.5 cm/m <sup>2</sup> or absolute dimensions >3.5 cm) Coarctation of aorta Uncontrolled hypertension despite medical treatment

whereas thyrotoxicosis occurs in ~1.6%. Diabetes mellitus is also more common, which may be associated with obesity and metabolic syndrome. Abnormal glucose homeostasis in TS may be due to a combination of reduced insulin response to glucose load, reduced insulin sensitivity and reduced beta cell function, suggesting that it is maybe a specific disorder unique to TS. Coeliac disease is seen in ~2–10% of TS although usually asymptomatic. An increased risk of IBD is also seen in TS, especially those with i(Xq) lineage.<sup>3,59,60</sup>

Abnormal liver function with raised ALT and GGT is thought to be related to hepatic steatosis and also small intrahepatic vascular anomalies. It was previously thought that oestrogen therapy may have a contributing role, but recent studies in fact show that mild improvement may be seen with oestrogen therapy.<sup>61</sup> Regular screening for thyroid disease, liver dysfunction and CD is recommended and imperative pre-conception.

Otitis media, middle ear effusions often requiring grommets insertion and subsequent cholesteatoma<sup>62</sup> are recognized complications of paediatric girls with TS. ENT surgeons, general practitioners, general paediatricians and physicians should consider the diagnosis of TS in a girl or woman with a history of ongoing ENT problems like recurrent otitis media, recurrent grommets insertion and cholesteatoma. Less well recognized is the progressive hearing loss, usually in the high frequency region, especially after the age of 30 years. The rate of decline in TS women aged 30–60 years is equivalent to those of 70–80 years in non-TS women.<sup>9</sup>

Women with TS appear to be at increased risk of cancers especially CNS tumours, bladder and urethral cancers. The increased risk of CNS tumours appears to be from non-malignant tumours like meningioma. Currently, there is no information on the relationship of risk with hormone therapy.<sup>63</sup>

While most girls and women with TS have normal intellect, ~10% may require special education and assistance. The majority, however, have specific learning difficulties involving non-verbal, perceptual, motor and visuospatial skills, which translates to difficulties in such aspects such as mathematics, driving, multitasking and social functioning especially reading social cues. Impaired peer relationship, higher anxiety, inflexibility, low self-esteem and preoccupation with keeping things in order are often reported.<sup>64</sup>

### An approach for provision of coordinated care

Provision of health care to the adolescent and adult with TS needs to be holistic and should address both the medical and non-medical aspects of the patient. Access to clinicians and allied health professionals aware of the complex and inter-related issues impacting on health of these individuals is needed. Support for TS individuals and families from TS support groups should be strongly encouraged and provides families with a source of valuable information. Often families may not wish to be involved with support groups at diagnosis, but this should be discussed again during adolescence as the young person may wish to be involved with other individuals with

TS. Specific needs of the TS young person and adult should be individualized with access to nurse specialist, psychologist and educational support. During the period of transition, addressing and paying attention to aspects relating to navigational planning and visuomotor integration may be necessary for a range of important day-to-day aspects of life such as driving training, choosing future career options and also organizing aspects of individual health care like medication and attendance in clinic. Psychosocial support is often lacking, but it should be an important part of clinical care of these girls and women. Group psychological intervention may improve self-esteem and generic skills in these young people.<sup>64</sup>

A comprehensive health evaluation should be performed in late adolescence prior to transition. These investigations should identify important health issues prior to transition to adult care (Table 5). In addition, crucial investigations from careful cardiovascular evaluation will allow appropriate risk of

AoD, especially during pregnancies. We believe that these issues should be discussed in adolescence by the treating paediatric team rather than deferring such discussions to the adult clinic, given the possibility of loss to follow-up during the transition period. However, there may be a case to conduct such investigations (e.g. cardiac MRI) once the young person is in the adult setting to ensure consistency of information and reporting given the need for future repeat evaluations. Discussion of such important issues may need to be individualized to the developmental maturity of each young person with TS. Close working relationship with adult clinicians and other paediatric subspecialties who may be involved in the care of the young person and adult with TS is needed to ensure consistencies in advice of some of the more unclear aspects of management of these individuals. Young adults with TS should be managed in dedicated TS clinics or by clinicians aware of the complex health issues encountered by these individuals and with

**Table 5** Suggested assessment in Turner syndrome prior to pubertal induction and transition

	Childhood	Young person—prior to transition
Auxology	Height, weight Pubertal assessment (from 10 years)	Height/weight Pubertal assessment
Growth hormone monitoring	IGF1 and bone age (if on growth hormone therapy) Thyroid function	Thyroid function
Ovarian reserve	FSH, AMH (at diagnosis) Pelvic ultrasound (prior to pubertal induction)	Pelvic ultrasound Counsel young person and family regarding fertility
Cardiovascular	Cardiac assessment and echocardiogram (diagnosis) Blood pressure (every clinic)	Cardiac assessment, echocardiogram ± MRI Blood pressure
Bone	Examine for scoliosis (before commencing growth hormone and annually)	DXA scan
Autoimmune	Thyroid peroxidase antibody (diagnosis) Thyroid function (diagnosis and then annually if on growth hormone) Coeliac screen (12 years)	Thyroid function Coeliac screen
ENT	Hearing test (diagnosis) ENT referral if appropriate	Hearing test
Renal	Renal ultrasound (diagnosis) Urine culture if any renal abnormalities	–
Liver	Liver function (12 years)	Liver function
Metabolic	–	Fasting glucose, lipids, HbA1C
Psychosocial	Review school performance	Vocational advice

access to other health professionals. Numerous clinicians will be involved in the health-care provision of these young people and adults, but the primary managing clinician in adult care should always involve an endocrinologist in the clinical care via the multidisciplinary clinic setting.

## Conclusion

With the range of varied issues encountered by the young person and adult with TS, transition is a complex process. This requires multidisciplinary care with a systematic approach to screen for associated medical conditions but individualized to address the needs of each young person with TS. Medical and non-medical aspects of TS girls and women need to be addressed in ongoing health-care provision by clinicians familiar with the spectrum of problems encountered by these women. Families and the young person should be made aware of the TS support group. Engaging TS women with ongoing follow-up in adulthood and regular health surveillance remains a challenging area.

## Conflict of Interest statement

The authors have no potential conflicts of interest.

## References

1. Stochholm K, Juul S, Juel K, et al. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. *J Clin Endocrinol Metab* 2006;91:3897–902.
2. Grossi A, Crinò A, Luciano R, et al. Endocrine autoimmunity in Turner syndrome. *Ital J Pediatr* 2013;39:79.
3. Bakalov VK, Gutin L, Cheng CM, et al. Autoimmune disorders in women with turner syndrome and women with karyotypically normal primary ovarian insufficiency. *J Autoimmun* 2012;38:315–21.
4. Hook EB. Exclusion of chromosomal mosaicism: tables of 90%, 95% and 99% confidence limits and comments on use. *Am J Hum Genet* 1977;29:94–7.
5. Jacobs P, Dalton P, James R, et al. Turner syndrome: a cytogenetic and molecular study. *Ann Hum Genet* 1997; 61:471–83.
6. Zhong Q, Layman LC. Genetic considerations in the patient with Turner syndrome—45,X with or without mosaicism. *Fertil Steril* 2012;98:775–79.
7. Wolff DJ, Van Dyke DL, Powell CM, et al. Laboratory guideline for Turner Syndrome. *Genet Med* 2010; 12:52–5.
8. Prakash S, Guo D, Maslen CL, et al. Single-nucleotide polymorphism array genotyping is equivalent to metaphase cytogenetics for diagnosis of Turner syndrome. *Genet Med* 2014;16:53–9.
9. Bondy CA; Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. *J Clin Endocrinol Metab* 2007;92:10–25.
10. Gicquel C, Gaston V, Cabrol S, et al. Assessment of Turner's syndrome by molecular analysis of the X chromosome in growth-retarded girls. *J Clin Endocrinol Metab* 1998;83:1472–6.
11. Wong SC, Burgess T, Cheung M, et al. The prevalence of turner syndrome in girls presenting with coarctation of the aorta. *J Pediatr* 2014;164:259–63.
12. Paterson WF, Hollman AS, Donaldson MD. Poor uterine development in Turner syndrome with oral oestrogen therapy. *Clin Endocrinol (Oxf)* 2002;56:359–65.
13. Hagen CP, Aksglaede L, Sørensen K, et al. Serum levels of anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. *J Clin Endocrinol Metab* 2010;95:5003–10.
14. Visser JA, Hokken-Koelega AC, Zandwijken GR, et al. Anti-Müllerian hormone levels in girls and adolescents with Turner syndrome are related to karyotype, pubertal development and growth hormone treatment. *Hum Reprod* 2013;28:1899–907.
15. Trolle C, Hjerrild B, Cleemann L, et al. Sex hormone replacement in Turner syndrome. *Endocrine* 2012; 41:200–19.
16. Davenport ML. Moving toward an understanding of hormone replacement therapy in adolescent girls: looking through the lens of Turner syndrome. *Ann NY Acad Sci* 2008;1135:126–37.
17. Sonnet E, Lacut K, Roudaut N, et al. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. *Clin Endocrinol (Oxf)* 2007;66:626–31.
18. Davenport ML. Evidence for early initiation of growth hormone and transdermal estradiol therapies in girls with Turner syndrome. *Growth Horm IGF Res* 2006;16 (Suppl A):S91–7.
19. Rosenfield RL, Devine N, Hunold JJ, et al. Salutory effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. *J Clin Endocrinol Metab* 2005;90:6424–30.

20. Janfaza M, Sherman TI, Larmore KA, et al. Estradiol levels and secretory dynamics in normal girls and boys as determined by an ultrasensitive bioassay: a 10 year experience. *J Pediatr Endocrinol Metab* 2006;19:901–9.
21. Courant F, Aksglaede L, Antignac JP, et al. Assessment of circulating sex steroid levels in prepubertal and pubertal boys and girls by a novel ultrasensitive gas chromatography-tandem mass spectrometry method. *J Clin Endocrinol Metab* 2010;95:82–92.
22. Quigley CA, Wan X, Garg S, et al. Effects of low-dose estrogen replacement during childhood on pubertal development and gonadotropin concentrations in patients with Turner Syndrome: results of a randomized, double-blind, placebo-controlled clinical trial. *J Clin Endocrinol Metab* 2014;99:E1754–64.
23. Ross JL, Quigley CA, Cao D, et al. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. *N Engl J Med* 2011;364:1230–42.
24. Fudge EB, Constantacos C, Fudge JC, et al. Improving detection of hypertension in girls with turner syndrome using ambulatory blood pressure monitoring. *Horm Res Paediatr* 2014;81:25–31.
25. Leung KC, Johannsson G, Leong GM, et al. Estrogen regulation of growth hormone action. *Endocr Rev* 2004;25:693–721.
26. De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. *J Clin Endocrinol Metab* 1986;62:536–41.
27. Kelly JJ, Rajkovic IA, O'Sullivan AJ, et al. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. *Clin Endocrinol (Oxf)* 1993;39:561–7.
28. Wolthers T, Hoffman DM, Nugent AG, et al. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. *Am J Physiol Endocrinol Metab* 2001;281:E1191–6.
29. O'Sullivan AJ, Crampton LJ, Freund J, et al. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. *J Clin Invest* 1998;102:1035–40.
30. Coutant R, de Casson FB, Rouleau S, et al. Divergent effect of endogenous and exogenous sex steroids on the insulin-like growth factor I response to growth hormone in short normal adolescents. *J Clin Endocrinol Metab* 2004;89:6185–92.
31. Nabhan ZM, Dimeglio LA, Qi R, et al. Conjugated oral versus transdermal estrogen replacement in girls with Turner syndrome: a pilot comparative study. *J Clin Endocrinol Metab* 2009;94:2009–14.
32. Kim NY, Lee DY, Kim MJ, et al. Estrogen requirements in girls with Turner syndrome; how low is enough for initiating puberty and uterine development? *Gynecol Endocrinol* 2012;28:130–3.
33. Cleemann L, Holm K, Fallentin E, et al. Uterus and ovaries in girls and young women with Turner syndrome evaluated by ultrasound and magnetic resonance imaging. *Clin Endocrinol (Oxf)* 2011;74:756–61.
34. Bannink EM, van Sassen C, van Buuren S, et al. Puberty induction in Turner syndrome: results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels. *Clin Endocrinol (Oxf)* 2009;70:265–73.
35. Piippo S, Lenko H, Kainulainen P, et al. Use of percutaneous estrogen gel for induction of puberty in girls with Turner syndrome. *J Clin Endocrinol Metab* 2004;89:3241–7.
36. Doerr HG, Bettendorf M, Hauffa BP, et al. Uterine size in women with Turner syndrome after induction of puberty with estrogens and long-term growth hormone therapy: results of the German IGLU Follow-up Study 2001. *Hum Reprod* 2005;20:1418–21.
37. McDonnell CM, Coleman L, Zacharin MR. A 3-year prospective study to assess uterine growth in girls with Turner's syndrome by pelvic ultrasound. *Clin Endocrinol (Oxf)* 2003;58:446–50.
38. Snajderova M, Mardesic T, Lebl J, et al. The uterine length in women with Turner syndrome reflects the postmenarcheal daily estrogen dose. *Horm Res* 2003;60:198–204.
39. O'Donnell RL, Warner P, Lee RJ, et al. Physiological sex steroid replacement in premature ovarian failure: randomized crossover trial of effect on uterine volume, endometrial thickness and blood flow, compared with a standard regimen. *Hum Reprod* 2012;27:1130–8.
40. Turtle EJ, Sule AA, Bath LE, et al. Assessing and addressing cardiovascular risk in adults with Turner syndrome. *Clin Endocrinol (Oxf)* 2013;78:639–45.
41. Rossouw JE, Anderson GL, Prentice RL, et al. Writing group for the women's health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. *JAMA* 2002;288:321–33.
42. Langrish JP, Mills NL, Bath LE, et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. *Hypertension* 2009;53:805–11.
43. Holroyd CR, Davies JH, Taylor P, et al. Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome. *Osteoporos Int* 2010;21:2093–9.

44. Hansen S, Brixen K, Gravholt CH. Compromised trabecular microarchitecture and lower finite element estimates of radius and tibia bone strength in adults with turner syndrome: a cross-sectional study using high-resolution-pQCT. *J Bone Miner Res* 2012;27:1794–803.
45. Hagman A, Loft A, Wennerholm UB, et al. Obstetric and neonatal outcome after oocyte donation in 106 women with Turner syndrome: a Nordic cohort study. *Hum Reprod* 2013;28:1598–609.
46. Alvaro Mercadal B, Imbert R, Demeestere I, et al. Pregnancy outcome after oocyte donation in patients with Turner's syndrome and partial X monosomy. *Hum Reprod* 2011;26:2061–8.
47. Bryman I, Sylvén L, Berntorp K, et al. Pregnancy rate and outcome in Swedish women with Turner syndrome. *Fertil Steril* 2011;95:2507–10.
48. Borgström B, Hreinsson J, Rasmussen C, et al. Fertility preservation in girls with turner syndrome: prognostic signs of the presence of ovarian follicles. *J Clin Endocrinol Metab* 2009;94:74–80.
49. Mortensen KH, Andersen NH, Gravholt CH. Cardiovascular phenotype in Turner syndrome—integrating cardiology, genetics, and endocrinology. *Endocr Rev* 2012;33:677–714.
50. Wong SC, Cheung M, Zacharin M. Aortic dilatation and dissection in Turner syndrome: What we know, what we are unclear about and what we should do in clinical practice? *Int J Adolesc Med Health* 2014;26:469–88.
51. Bondy CA. Aortic dissection in Turner syndrome. *Curr Opin Cardiol* 2008;23:519–26.
52. Ostberg JE, Brookes JA, McCarthy C, et al. A comparison of echocardiography and magnetic resonance imaging in cardiovascular screening of adults with Turner syndrome. *J Clin Endocrinol Metab* 2004;89:5966–71.
53. Carlson M, Airhart N, Lopez L, et al. Moderate aortic enlargement and bicuspid aortic valve are associated with aortic dissection in Turner syndrome: report of the international turner syndrome aortic dissection registry. *Circulation* 2012;126:2220–6.
54. Mortensen KH, Erlandsen M, Andersen NH, et al. Prediction of aortic dilation in Turner syndrome—enhancing the use of serial cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2013;15:47.
55. Chalas Boissonnas C, Davy C, Marszalek A, et al. Cardiovascular findings in women suffering from Turner syndrome requesting oocyte donation. *Hum Reprod* 2011;26:2754–62.
56. Wong SC, Ehtisham S, Cheung MM, et al. Cardiovascular evaluation in Turner Syndrome: the evidence, the reality and the challenges. *Int J Cardiol* 2014;173:341–2.
57. Practice Committee of American Society for Reproductive Medicine. Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome. *Fertil Steril* 2012;97:282–4.
58. Cabanes L, Chalas C, Christin-Maitre S, et al. Turner syndrome and pregnancy: clinical practice. Recommendations for the management of patients with Turner syndrome before and during pregnancy. *Eur J Obstet Gynecol Reprod Biol* 2010;152:18–24.
59. Sybert VP, McCauley E. Turner's Syndrome. *N Engl J Med* 2004;351:1227–38.
60. Hayward PA, Satsangi J, Jewell DP. Inflammatory bowel disease and the X chromosome. *QJM* 1996;89:713–8.
61. Lee MC, Conway GS. Liver dysfunction in Turner syndrome and its relationship to exogenous oestrogen. *Eur J Gastroenterol Hepatol* 2013;25:1141–5.
62. Lim D, Gault E, Kubba H, et al. Cholesteatoma has a high prevalence in Turner syndrome, highlighting the need for earlier diagnosis and the potential benefits of otoscopy training for paediatricians. *Acta Paediatr* 2014; 103:e282–7.
63. Schoemaker MJ, Swerdlow AJ, Higgins CD, et al. Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study. *Lancet Oncol* 2008;9:239–46.
64. Chadwick PM, Smyth A, Liao LM. Improving self-esteem in women diagnosed with Turner Syndrome: results of a pilot intervention. *J Pediatr Adolesc Gynecol* 2014;27:129–32.